Bio

As co-founder and co-director of ALMA Clinic, Dr. Nataly Beck is a psychiatrist who is passionate about providing compassionate, evidence-based, culturally sensitive, and language-concordant care to patients, especially including those from the Hispanic or Latin-American community. Originally from Lima, Peru, she immigrated to the US with her family at a young age. After attending the University of Tennessee-Knoxville, she attended Yale School of Medicine and then completed her psychiatry residency at Vanderbilt University Medical Center. As a Clinical Assistant Professor at Stanford, she co-founded ALMA Clinic (formerly known as La Clínica Latina) in 2021 and has been inspired to see the impact that the clinic has had on many Hispanic and Latin-American patients. Dr. Beck is honored to have the opportunity to co-lead the team of providers, graduate and undergraduate students, and others at Stanford Medicine that have the united goal of providing excellent care to patients as well as to advance mental health care in the Hispanic and Latin-American community.


Como cofundadora y codirectora de la Clínica ALMA, la Dra. Nataly Beck es una psiquiatra apasionada por brindar atención compasiva, basada en la evidencia, culturalmente sensible y en el idioma del paciente, especialmente a aquellos de la comunidad hispana o latinoamericana. Originaria de Lima, Perú, emigró a Estados Unidos con su familia a una edad temprana. Tras estudiar en la Universidad de Tennessee-Knoxville, cursó sus estudios de medicina en la Facultad de Medicina de Yale y completó su residencia en psiquiatría en el Centro Médico de la Universidad de Vanderbilt. Como profesora clínica adjunta en Stanford, cofundó la Clínica ALMA (anteriormente conocida como La Clínica Latina) en 2021 y se siente inspirada al ver el impacto que la clínica ha tenido en muchos pacientes hispanos y latinoamericanos. La Dra. Beck se siente honrada de tener la oportunidad de codirigir el equipo de profesionales, estudiantes de posgrado y pregrado, y demás personal de Stanford Medicine, quienes comparten el objetivo de brindar una atención excelente a los pacientes y de promover la salud mental en la comunidad hispana y latinoamericana.

Clinical Focus

  • Psychiatry
  • Latino Mental Health

Academic Appointments

  • Clinical Assistant Professor, Psychiatry and Behavioral Sciences

Professional Education

  • Board Certification: American Board of Psychiatry and Neurology, Psychiatry (2018)
  • Residency, Vanderbilt University Medical Center, General Psychiatry (2018)
  • M.D., Yale University, Medicine (2014)
  • B.S., University of Tennessee, Knoxville, Biomedical Engineering and Biochemistry (2008)

Contact

  • Academic
    nbeck@stanford.edu
    University - Staff Department: Psych/General Psychiatry and Psychology (Adult) Position: Clinical Assistant Professor
    University - Affiliate Department: Psychiatry and Behavioral Sciences
  • Clinical (Primary)  Psychiatry Clinic 401 Quarry Rd Rm 2303 Stanford, CA 94305 (650) 724-9900 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5717
  • Other Names:
    Nataly Sumarriva Beck
    Nataly S Beck

All Publications

  • Assessing the impact of COVID-19 on psychiatric clinical trials. Journal of psychiatric research Cannon, J. A., Strathman, A. R., Warner, S., Flignor, J., Beck, N. S. 2022; 148: 127-130

    Abstract

    OBJECTIVE: COVID-19 and associated measures to control the spread of the COVID-19 has significantly impacted clinical research. This study aimed to determine the impact COVID-19 has had on psychiatric clinical trials and to assess whether certain trial areas or trial types were differentially affected.METHODS: We used information from ClinicalTrials.gov, the largest online database of clinical trial information, to examine changes in psychiatric clinical trials from January 2010-December 2020.RESULTS: Clinical trial initiation decreased in 2020, with a year-on-year percent change in trial initiation of -5.4% versus an expected percent change based on forecasting observed trends from 2010 to 2019 of 8.6%. When broken down by disease area, the distribution of trials observed in 2020 was significantly different from the predicted distribution (p<0.00001). The greatest decrease in trial initiation was seen in Schizophrenia-specific trials, with an observed percent change of -29.2% versus an expected percent change of 3.2%. Conversely, anxiety trials saw a significant increase in trial initiation during 2020, with an observed percent change of 24.6% versus an expected percent change of 16.0%. When assessing interventional versus observational studies, data showed a significant increase in initiation of observational psychiatric clinical trials (p<0.05), and a significant decrease in initiation of interventional psychiatric clinical trials (p<0.01). When data was analyzed on a month-by-month time scale, 7/12 months in 2020 showed significant decreases when compared to initiation during matching months over prior years, and a single month, June, showed a significant increase.CONCLUSION: COVID-19 has had significant impacts on the initiation of psychiatric clinical trials over 2020, and this decrease in trial initiation may have long-term impacts on the development and assessment of psychiatric treatments and therapeutics.

    View details for DOI 10.1016/j.jpsychires.2022.01.017

    View details for PubMedID 35123324

  • Ethical Issues in Psychopharmacology. Focus (American Psychiatric Publishing) Beck, N. S., Kim, D. S., Dunn, L. B. 2021; 19 (1): 53-58

    View details for DOI 10.1176/appi.focus.20200043

    View details for PubMedID 34483768

  • Ethical Issues in Schizophrenia. Focus (American Psychiatric Publishing) Beck, N. S., Ballon, J. S. 2020; 18 (4): 428–31

    View details for DOI 10.1176/appi.focus.20200030

    View details for PubMedID 33343254

  • Early Psychosis: Diagnosis and Treatment Current Psychopharmacology Beck, N. S., Lean, M. L., Hardy, K. V., Ballon, J. S. 2020

    View details for DOI 10.2174/2211556009999200723123322